Skip to content
value.today

Evommune, Inc.: financial analysis

Ratios worked out from 3 fiscal years of Evommune, Inc.'s statements, compared with 665 companies in Biotechnology.

Operating margin, 2025
-623.6%
Biotechnology: -60.5%
Return on equity, 2025
-224.6%
Biotechnology: -61.0%
Free cash flow margin, 2025
-589.9%
Biotechnology: -61.5%

Evommune, Inc. scorecard#

Passes 4 of the 13 checks that could be worked out: strongest in valuation (1 of 5), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.4×Price to book 1.4× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median21.7×Price to sales 21.7× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-27.2%Free cash flow is -27.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • ✓Revenue grew in the newest year85.7%Revenue up 85.7% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-11.22 vs -45.29Diluted EPS -11.22 in fiscal 2025 against -45.29 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$69 MNet income -$69 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✗Operating margin above its peers' median-623.6%-623.6% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-224.6%-224.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 2
    • ✓Short-term assets cover short-term liabilities8.6×Current ratio 8.57 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • ✓Altman Z-score outside the distress zone6.93Z-score 6.93 (safe zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year307.0%Diluted shares up 307.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Worth a look

  • Net loss of $69 million.
  • Free cash flow was negative: -$77 million.
  • The share count rose 307.0% in the year.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

2of 7(2 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profitno
  • Operations brought in cashno
  • Return on assets roseyes
  • Cash from operations exceeds profitno
  • Long-term debt fell against assetsnot on file
  • Current ratio roseyes
  • No new shares issuedno
  • Gross margin rosenot on file
  • Asset turnover roseno

Altman Z-score

A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.

6.93Safe zone(above 2.99, where the formula's author found few failures)
The five parts of the Altman Z-score
PartRatioWeightPoints
Working capital to assets0.60× 1.20.72
Retained earnings to assets-0.98× 1.4-1.38
Operating income to assets-0.36× 3.3-1.19
Market value to liabilities14.53× 0.68.72
Revenue to assets0.06× 10.06

Profitability#

Evommune, Inc.: profitability by fiscal year
Fiscal yearTrend202520242023Median of peersAhead of
Operating margin-623.6%——-60.5%7%
Net margin-529.8%-954.4%—-68.9%10%
Return on equity-224.6%——-61.0%11%
Return on assets-45.8%-87.8%—-44.4%49%

Growth#

Evommune, Inc.: growth by fiscal year
Fiscal yearTrend202520242023Median of peersAhead of
Revenue growth85.7%——15.8%80%

Financial strength#

Evommune, Inc.: financial strength by fiscal year
Fiscal yearTrend202520242023Median of peersAhead of
Current ratio8.57×2.64×—4.39×73%
Equity share of assets91.4%-189.6%—64.7%88%

Cash#

Evommune, Inc.: cash by fiscal year
Fiscal yearTrend202520242023Median of peersAhead of
Free cash flow$-77 M$-58 M—$-40 M35%
Free cash flow margin-589.9%-832.7%—-61.5%10%
Capital spending share of revenue1.9%1.3%—1.7%—

Shareholder returns#

Evommune, Inc.: shareholder returns by fiscal year
Fiscal yearTrend202520242023Median of peersAhead of
Change in share count307.0%——17.3%4%

Efficiency#

Evommune, Inc.: efficiency by fiscal year
Fiscal yearTrend202520242023Median of peersAhead of
Asset turnover0.09×0.09×—0.26×24%

How each figure is worked out#

Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Capital spending share of revenue
Capital spending as a share of revenue.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Evommune, Inc.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that Evommune, Inc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Evommune, Inc.